Deuterated drugs and biomarkers in the COVID-19 pandemicJansen-van Vuuren, Ross D. (Avtor) Jedlovčnik, Luka (Avtor) Košmrlj, Janez (Avtor) Massey, Thomas E. (Avtor) Derdau, Volker (Avtor) COVID-19hydrogen isotopesinhibitorsmetabolismpharmaceuticalsCoronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan (China) in December 2019, COVID-19 rapidly spread globally, resulting in the COVID-19 pandemic. Carriers of the SARS-CoV-2 can experience symptoms ranging from mild to severe (or no symptoms whatsoever). Although vaccination provides extra immunity toward SARS-CoV-2, there has been an urgent need to develop treatments for COVID-19 to alleviate symptoms for carriers of the disease. In seeking a potential treatment, deuterated compounds have played a critical role either as therapeutic agents or as internal MS standards for studying the pharmacological properties of new drugs by quantifying the parent compounds and metabolites. We have identified >70 examples of deuterium-labeled compounds associated with treatment of COVID-19. Of these, we found 9 repurposed drugs and >20 novel drugs studied for potential therapeutic roles along with a total of 38 compounds (drugs, biomarkers, and lipids) explored as internal mass spectrometry standards. This review details the synthetic pathways and modes of action of these compounds (if known), and a brief analysis of each study.20222023-02-14 11:29:22Članek v reviji144314UDK: 547.8:546.11ISSN pri članku: 2470-1343DOI: 10.1021/acsomega.2c04160COBISS_ID: 131181827sl